PepGuide

Modified hGH fragment peptide ( investigational fat-loss agent)

HGH fragment 176-191

A growth hormone fragment peptide marketed for fat loss, but human evidence for meaningful body-composition effects is weak.

Evidence:
Insufficient evidence summarized
Status:
Not FDA-approved
Reviewed:
2026-08-03

Also known as: HGH fragment 176-191, HGH-FRAG, HGH-FRAG 176-191, Anti-obesity drug fragment, AOD9604

What is HGH fragment 176-191?

A growth hormone fragment peptide marketed for fat loss, but human evidence for meaningful body-composition effects is weak.

This profile is educational. It organizes publicly discussed research context for HGH fragment 176-191 and related naming aliases — it is not a treatment guide.

Proposed mechanism

Proposed lipolytic fragment of human growth hormone C-terminal region, theorized to stimulate fat metabolism without full GH effects.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Insufficient evidence summarized

Preclinical evidence grade: Early-stage human research

AOD-9604 was developed from hGH fragment research. Despite marketing claims, available evidence suggests limited efficacy for fat loss in humans. A TGA review in Australia did not support efficacy claims. Human evidence remains limited and inconsistent; much discussion is anecdotal or preclinical. Often grouped with cosmetic/weight peptides but lacks robust clinical validation.

Key uncertainties

  • Any clinically meaningful fat-loss effect in humans
  • Nasal and other route bioavailability poorly characterized

Research areas being studied

  • Body composition
  • Lipolysis research

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

  • Limited systematic adverse event data
  • Headache reported anecdotally

Additional risks & considerations

  • Unproven efficacy
  • Unregulated product quality
  • Misleading marketing claims

Regulatory status

Not FDA-approved

Not FDA approved; prohibited in some sports contexts (WADA-related discussions).

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

What is HGH fragment 176-191?

A growth hormone fragment peptide marketed for fat loss, but human evidence for meaningful body-composition effects is weak.

How does HGH fragment 176-191 work (proposed mechanism)?

Proposed lipolytic fragment of human growth hormone C-terminal region, theorized to stimulate fat metabolism without full GH effects.

What is HGH fragment 176-191 being researched for?

HGH fragment 176-191 has been discussed in research contexts including: Body composition, Lipolysis research.

What does current evidence say about HGH fragment 176-191?

Insufficient evidence summarized. AOD-9604 was developed from hGH fragment research. Despite marketing claims, available evidence suggests limited efficacy for fat loss in humans. A TGA review in Australia did not support efficacy claims. Human evidence remains limited and inconsistent; much discussion is anecdotal or preclinical. Often grouped with cosmetic/weight peptides but lacks robust clinical validation.

What safety considerations are noted for HGH fragment 176-191?

Reported or discussed considerations include: Limited systematic adverse event data; Headache reported anecdotally; Unproven efficacy; Unregulated product quality; Misleading marketing claims. This is educational information, not medical advice.

Is HGH fragment 176-191 FDA approved?

Not FDA-approved. Not FDA approved; prohibited in some sports contexts (WADA-related discussions).

References & sources

  • Heffernan MA et al. (2001). AOD9604: pharmacological review — Expert Opin Investig Drugs. Evidence type: review.

Prefer interactive tools? Open the PepGuide library entry for HGH fragment 176-191 or ask PepGuide AI.

Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.